Durham, NC – According to filings with the U.S. Securities and Exchange Commission, Entegrion is raising $20,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Albert Valada played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Entegrion
Entegrion is a life sciences company dedicated to providing innovative solutions to improve clinicians ability to effectively manage hemostasis in patients. Our products bring about major changes to the critical pathways in the diagnosis and treatment of patient coagulopathies, enabling clinicians to rapidly and effectively advance care in both the hospital and field environments. From research and development through delivery to market, we partner with leading scientists, clinicians, and industry specialists to provide products that enable doctors to improve clinical outcomes for patients whose hemostatic state may be compromised. Entegrions products are designed to address the needs of clinicians in both civilian and military medicine. The U.S. Department of Defense has been a major funding partner for the advancement of our technologies, awarding more than $100 million in product development contracts since the Company’s inception.

To learn more about Entegrion, visit http://www.entegrion.com/

Contact:
Albert Valada, Chief Executive Officer
919-536-1500
avalada@entegrion.com

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved